

Q2 2025 Results

Clinical Trial Appendix




Disclosures

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeOne's research, discovery, pre-clinical and clinical programs and plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeOne undertakes no duty to update such information unless required by law.




BeOne pipeline snapshot

As of: 23 Jul 2025



Across three therapy areas:



* Including IITs



Project movements since Q1 2025 update

As of: 23 Jul 2025

New to Phase I/Ib	New to Phase II	New to Pivotal Trial	New Submission	Approved
BTK CDAC BGB-16673-107 CSU ¹		Tislelizumab BGB-A317-316 SubQ ² BTK CDAC BGB-16673-303 R/R CLL (vs. investigator's choice, CN only study) BTK CDAC BGB-16673-304 R/R CLL ² (vs. Pirtobrutinib) Tarlatamab 20240178 1L ES-SCLC (+Durva + chemo induction; +Durva maintenance)	Sonrotoclax 201 (R/R MCL) in CN Sonrotoclax 202 (R/R CLL) in CN Zanubrutinib 114 (Tablet Formulation) in BR Tarlatamab 20230273 (3L+ SCLC) in CN (priority review) Tarlatamab 20210004 (2L SCLC) in CN Tislelizumab (305 1L GC) in JP (312 1L SCLC) in AU (Alt Dosing Q6W) in EU	Zanubrutinib 114 (Tablet Formulation) in US Zanubrutinib (R/R FL) in BR Zanidatamab (BTC) in CN ³ Tislelizumab (305 1L GC) in AU, UK (309 1L NPC) in AU, EU (312 1L ES-SCLC) in EU (Alt Dosing Q2W /Q4W) in US

¹ Chronic spontaneous urticaria

² Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

³ Conditional approval

AU – Australia; BR – Brazil; CN – China; EU – European Union; UK – United Kingdom; US – United States



Projects removed since Q1 2025 update

As of: 23 Jul 2025

Removed from Phase I	Removed from Phase II	Removed from Phase III
DGKζi (BGB-30813)		



Global clinical development pipeline

As of: 05 Aug 2025

Phase 1		Phase 2		Phase 3		Accepted Submissions Major markets	
Sonrotoclax	BCL2i	BG-60366	EGFR CDAC	Zanubrutinib	BTKi	Zanubrutinib	BTKi
● 101 B-cell malignancies		● 101 Solid tumors		● 215 B-cell malignancies		● 114 Tablet formulation (EU)	
● 102 B-cell malignancies		BG-T187	EGFR x MET x MET TsAb	Sonrotoclax	BCL2i	Sonrotoclax	BCL2i
● 103 AML/MDS		● 101 Solid tumors		● 203 R/R WM		● 201 R/R MCL (CN)	
● 105 R/R MM t(11;14)		BGB-R046	IL-15 prodrug	● 204 TN CLL/SLL		● 202 R/R CLL (CN)	
● 108 Dose ramp-up		● 101 Solid tumors		BGB-16673	BTK CDAC	Tarlatamab⁴	DLL3 x CD3 BiTE[®]
BGB-16673	BTK CDAC	BGB-26808	HPK1i	● 101 R/R CLL & R/R WM		● 20230273 3L+ SCLC (CN)	
● 101 B-cell malignancies		● 101 Solid tumors		● 102 R/R CLL		● 20210004 2L SCLC (CN)	
● 102 B-cell malignancies		Tarlatamab⁴	DLL3 x CD3 BiTE[®]	Blinatumomab⁴	CD19 x CD3 BiTE[®]	Tislelizumab	PD-1 mAb
● 104 B-cell malignancies		● 20240124 2L+ SCLC (+B7-H3)		● 20190359 R/R BP-ALL		● 315 Neo/adj NSCLC (EU)	
● 107 Chronic spontaneous urticaria		● 20230298 2L+ SCLC SubQ formulation**		Tarlatamab⁴	DLL3 x CD3 BiTE[®]	● Alternate dosing Q6W (US, CN, EU)	
BGB-21447	BCL2i	BGB-53038	Pan-KRAsi	● 20240092 2L+ SCLC (Alt dosing)			
● 101 B-cell malignancies		● 101 Solid tumors		BGB-45035	IRAK4 CDAC		
● 102 Metastatic breast cancer		BG-C477	CEA ADC	● 201 Rheumatoid Arthritis**			
BGB-43395	CDK4i	BG-C137	FGFR2b ADC				
● 101/102 Solid tumors		● 101 Solid tumors					
BG-C9074¹	B7-H4 ADC	BGB-B3227	MUC1 x CD16A BsAb				
● 101 Solid tumors		● 101 Solid tumors					
BG-68501²	CDK2i	BGB-B2033	GPC3 x 4-1BB BsAb				
● 101 Solid tumors		● 101 Solid tumors					
BGB-A3055	CCR8 mAb	Xaluritamig⁴	STEAP1 x CD3 XmAb[®]				
● 101 Solid tumors		● 20180146 mCRPC					
BGB-B455	CLDN 6 x CD3 BsAb	BGB-45035	IRAK4 CDAC				
● 101 Solid tumors		● 101 Immunology & Inflammation					
BG-58067	MTA Coop. PRMT5i						
● 101 Solid tumors							
BG-89894³	MAT2Ai						
● 101 Solid tumors							
BG-C354	B7-H3 ADC						
● 101 Solid tumors							

● Heme ● Breast / Gyn ● Other Cancers
● Lung ● GI ● I&I

Accepted submissions shown for major markets US, CN, EU, JP

1) DualityBio collaboration, 2) Ensem collaboration, 3) CSPC collaboration, 4) Amgen collaboration, 5) Zymeworks/Jazz collaboration.

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details, as of February 27, 2025

** Trial is listed on clinicaltrials.gov, but may not have subjects enrolled



Our pipeline includes diverse modalities and mechanisms across disease franchises

As of: 23 Jul 2025

Breast/Gynecologic



CDK4i

CDK2i

BCL2i

KAT6A/Bi*

B7-H4 ADC

Claudin 6 x CD3 BsAb

CDK2 CDAC*

Lung



Pan-KRASI

MTA Cooperative PRMT5i

MAT2Ai

CEA ADC

B7-H3 ADC

EGFR CDAC

EGFR x MET x MET TsAb

EGFR x MET x MET ADC*

Gastrointestinal



Pan-KRASI

MTA Cooperative PRMT5i

MAT2Ai

FGFR2b ADC

CEA ADC

GPC3 x 4-1BB BsAb

MUC1 x CD16A BsAb

Pan-tumor

HPK1i

CCR8 mAb

IL-15 prodrug

Small molecule

Protein degrader

Bi/Tri-specific

mAb

ADC

Cytokine therapy

* Not yet in the clinic

Target(i), target inhibitor; CDAC, chimeric degradation activating compound; ADC, antibody drug conjugate; BsADC, bispecific ADC; TsADC, trispecific ADC; BsAb, bispecific antibody; TsAb, trispecific antibody
BeOne has global rights for CDK2i (Ensem partnership), B7-H4 ADC (DualityBio partnership), MAT2Ai (CSPC Zhongqi Pharmaceutical Technology)



Building leadership in solid tumors with innovative NMEs

As of: 23 Jul 2025

	Phase 1			Phase 2	Phase 3	
Breast/ Gynecologic Cancers	BGB-C9074-101 B7-H4-ADC Breast (other ST)	BGB-43395-101/102 CDK4i Breast (other ST)	BGB-21447-102 BCL2i Breast			
	BG-68501-101 CDK2i Breast (other ST)	BGB-B455-101 Claudin 6 x CD3 BsAb Gyn (other ST)				
Gastro- intestinal	BG-53038-101 Pan-KRAsi GI and lung	BGB-B2033-101 GPC3 x 4-1BB BsAb Solid Tumors	BG-C137-101 FGFR2b ADC GI			
	BG-C477-101 CEA ADC GI and Lung	BGB-B3227-101 MUC1 x CD16A BsAb Lung and GI				
Lung	AMG757 20240124 Tarlatamab DLL3 x CD3 BiTE® 2L+ SCLC (+B7-H3) (Global)	AMG757 20230298 Tarlatamab DLL3 x CD3 BiTE® 2L+ SCLC (SubQ) (Global)	BGB-C354-101 B7-H3 ADC Lung, GI and HNSCC	BG-T187-101 EGFR x MET x MET TsAb Lung and GI	AMG757 20240092 Tarlatamab DLL3 x CD3 BiTE® 2L+ SCLC (Alt dosing) (Global)	AMG757 20210004 Tarlatamab DLL3 x CD3 BiTE® 2L SCLC (Global)
	BG-60366-101 EGFR-CDAC Lung	BGB-58067-101 MTA-coop PRMT5i Lung and GI	BG-89894-101 MAT2Ai Lung and GI		AMG757 20230273 Tarlatamab DLL3 x CD3 BiTE® 3L+ SCLC (CN)	AMG757 20200041 Tarlatamab DLL3 x CD3 BiTE® 1L ES-SCLC Maintenance. (Global)
Pan-tumor/ Other	BGB-26808-101 HPK1i Solid Tumors	BGB-A3055-101 CCR8 MAb Solid Tumors	BGB-R046-101 IL-15 prodrug Solid Tumors		AMG757 20230016 Tarlatamab DLL3 x CD3 BiTE® LS-SCLC (Global)	AMG757 20240178 Tarlatamab DLL3 x CD3 BiTE® 1L ES-SCLC ¹ Induction. + Maint. (Global)
	AMG509 20180146 Xaluritamig STEAPI x CD3 XmAb® mCRPC (Global)					

Studies in “close-out” status excluded

¹Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Refer to Glossary abbreviations



Building leadership in solid tumors with LCM

As of: 23 Jul 2025

	Phase 1	Phase 2	Phase 3	Approved ¹		
Breast/ Gynecologic Cancers			BGB-290-302 Pamiparib PARPi 2L PSOC	BGB-290-102 Pamiparib PARPi 3L+ PSOC, PROC	Baituowei (Goserelin) Breast, Prostate	
Gastro- intestinal		BGB-A317-209 Tislelizumab PD-1 mAb Resect MSI-H/ dMMR CRC	ZWI-ZW25-301 Zanidatamab HER2 mAb 1L HER2+ GEA	BGB-A317-301 Tislelizumab PD-1 mAb 1L HCC	BGB-A317-302 Tislelizumab PD-1 mAb 2L ESCC	BGB-A317-305 Tislelizumab PD-1 mAb 1L GC
				BGB-A317-306 Tislelizumab PD-1 mAb 1L ESCC	BGB-A317-208 Tislelizumab PD-1 mAb 2L/3L+HCC	ZWI-ZW25-203 Zanidatamab HER2 BsAb HER2+ 2L+ BTC (CN) ²
				BGB-A317-304 Tislelizumab PD-1 mAb 1L Non-sq. NSCLC	BGB-A317-307 Tislelizumab PD-1 mAb 1L Sq. NSCLC	BGB-A317-303 Tislelizumab PD-1 mAb 2/3L NSCLC
Lung				BGB-A317-312 Tislelizumab PD-1 mAb 1L ES-SCLC	BGB-A317-309 Tislelizumab PD-1 mAb 1L NPC	BGB-A317-315 Tislelizumab PD-1 mAb Neo/adj. NSCLC
Pan-tumor/ Other	BGB-A317-103 Tislelizumab PD-1 mAb SubQ Formulation		BGB-A317-310 Tislelizumab PD-1 mAb 1L UBC	BGB-A317-290-LTE1 Multiple assets LTE Solid Tumors	BGB-A317-204 Tislelizumab PD-1 mAb 2L UC	BGB-A317-209 Tislelizumab PD-1 mAb Late Line MSI-H or dMMR
			BGB-A317-316 Tislelizumab PD-1 mAb SubQ Formulation ³			

Studies in "close-out" status excluded

¹Approved in at least one major market, such as US, CN, EU, and/or JP

²Conditional approval

³Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Refer to Glossary abbreviation



A leader in hematology / I&I portfolio – innovative NMEs

As of: 23 Jul 2025

	Phase 1		Phase 2		Phase 3	
AML/MDS, Multiple Myeloma, Other Heme	BGB-11417-103 Sonrotoclax BCL2i AML/MDS	BGB-11417-105 Sonrotoclax BCL2i R/R Multiple Myeloma t(11;14)				
B-Cell	BGB-21447-101 BCL2i B-Cell Malignancies		BGB-11417-201 Sonrotoclax BCL2i R/R MCL	BGB-11417-202 Sonrotoclax BCL2i CLL/SLL (CN)	BGB-11417-301 Sonrotoclax BCL2i TN CLL combo + zanu	BGB-16673-302 BTK CDAC R/R CLL
	BGB-11417-102 Sonrotoclax BCL2i B-Cell Malign.(CN)	BGB-11417-101 Sonrotoclax BCL2i mono & combo w/ zanu	BGB-11417-108 Sonrotoclax BCL2i B-Cell Malign. dose ramp-up	BGB-11417-203 Sonrotoclax BCL2i R/R WM	BGB-11417-204 Sonrotoclax BCL2i TN CLL	BGB-11417-302 Sonrotoclax BCL2i R/R MCL
						BGB-16673-303 BTK CDAC R/R CLL (CN)
	BGB-16673-101 BTK CDAC B-Cell Malign.	BGB-16673-102 BTK CDAC B-Cell Malign. (CN)	BGB-16673-104 BTK CDAC B-Cell Malign. combos	BGB-16673-101/102 BTK CDAC R/R CLL & R/R WM (exp.)	BGB-11417-303 Sonrotoclax BCL2i R/R CLL/SLL ¹	BGB-16673-304 BTK CDAC R/R CLL v. pirtobrutinib
I&I	BGB-45035-101 IRAK4 CDAC HV & AD, PN	BGB-16673-107 BTK CDAC Chronic Spontaneous Urticaria				



A leader in hematology / I&I with LCM

As of: 23 Jul 2025

	Phase 1	Phase 2	Phase 3	Approved ¹			
AML/MDS, Multiple Myeloma, Other Heme		BLINCYTO® CD3/CD19 BiTE Pediatric R/R BP-ALL	BGB-A317-314 Tislelizumab PD-1 R/R cHL (CN)	BGB-A317-203 Tislelizumab PD-1 R/R cHL			
B-Cell		BGB-3111-215 Zanubrutinib BTKi Prev. BTKi Tx intolerant	BGB-3111-111 Zanubrutinib BTKi R/R CLL/SLL, WM, MCL (JP) BGB-3111-304 Zanubrutinib BTKi TN CLL Ven combo	BGB-3111-306 Zanubrutinib BTKi TN MCL BGB-3111-LTE1 Zanubrutinib BTKi B-cell malignancies	BGB-3111-308 Zanubrutinib BTKi R/R MZL, R/R FL	BGB-3111-206 Zanubrutinib BTKi R/R MCL BGB-3111-212 Zanubrutinib BTKi R/R FL BGB-3111-214 Zanubrutinib BTKi R/R MZL BGB-3111-114 Zanubrutinib BTKi Tablet formulation	BGB-3111-302 Zanubrutinib BTKi TN & R/R WM BGB-3111-304 Zanubrutinib BTKi TN CLL/SLL BGB-3111-305 Zanubrutinib BTKi R/R CLL/SLL
I&I			BGB-3111-309 Zanubrutinib BTKi PMN				

Studies in “close-out” status excluded

Refer to Glossary abbreviation

¹Approved in at least one major market, such as US, CN, EU, and/or JP



Trial detail

- **BRUKINSA[®]**(zanubrutinib)
- **Sonrotoclax**
- **BGB-16673 BTK CDAC**
- **Other Hematology Assets**
- **TEVIMBRA[®]** (tislelizumab)
- **Other Solid Tumor Assets**
- **Immunology and Inflammation Assets**



BRUKINSA®

Foundational asset in hematology portfolio

As of: 23 Jul 2025

Trial	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-3111-111	Phase 2	NCT04172246	B-Cell Malignancies	55 (JP)	-	TEAEs and ORR	Enrolling (JP) / Maint. (ROW)
BGB-3111-215	Phase 2	NCT04116437	Previous BTKi Tx - ibrutinib/acalofur intolerant	96	-	TEAEs	Maintenance
BGB-3111-218	Phase 2	NCT05068440	CD79b R/R DLBCL	66	-	ORR	Closeout
BGB-3111-304 (SEQUOIA)	Phase 3	NCT03336333	TN CLL/SLL	784	Venetoclax (arm D)	PFS	Approved / Maint. (arm D)
BGB-3111-306 (MANGROVE)	Phase 3	NCT04002297	TN MCL	510	Rituximab	PFS	Maintenance
BGB-3111-308 (MAHOGANY)	Phase 3	NCT05100862	R/R MZL and FL	780	Rituximab, Obinutuzumab	PFS	Enrolling
BGB-3111-LTE1	Phase 3	NCT04170283	B-Cell Malignancies	937	Tislelizumab	TEAEs	Enrolling
BGB-3111-114	Phase 1	NCT05767398	Healthy volunteers	58	-	PK	Approved
BGB-3111-206	Phase 2	NCT03206970	R/R MCL	86	-	ORR	Approved
BGB-3111-212 (ROSEWOOD)	Phase 2	NCT03332017	R/R FL	217	Obinutuzumab	ORR	Approved
BGB-3111-214 (MAGNOLIA)	Phase 2	NCT03846427	R/R MZL	68	-	ORR	Approved
BGB-3111-302 (ASPEN)	Phase 3	NCT03053440	TN & R/R WM	201	-	CR\VGPR	Approved
BGB-3111-305 (ALPINE)	Phase 3	NCT03734016	R/R CLL	652	-	ORR	Approved



¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

Refer to Glossary abbreviations



Sonrotoclax

Potential best-in-class BCL2 inhibitor with differentiated profile

As of: 23 Jul 2025

Trial	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-11417-101	Phase 1	NCT04277637	B-Cell Malignancies & NHL	437	Zanubrutinib, Obinutuzumab	TEAEs, MTD	Maintenance
BGB-11417-102	Phase 1	NCT04883957	B-Cell Malignancies	64 (CN)	-	TEAEs, MTD	Maintenance
BGB-11417-103	Phase 1	NCT04771130	AML/MDS	260	Azacitidine	TEAEs, CR, mOR	Enrolling
BGB-11417-105	Phase 1	NCT04973605	R/R MM with t(11;14)	246	Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide	TEAEs, ORR, VGPR, CR	Enrolling
BGB-11417-108	Phase 1	NCT06697184	B-Cell Malignancies	56	Zanubrutinib	TLS	Enrolling
BGB-11417-201	Phase 2	NCT05471843	R/R MCL	126	-	TEAEs, ORR	Maintenance
BGB-11417-202	Phase 2	NCT05479994	R/R CLL/SLL	100	-	ORR	Maintenance
BGB-11417-203	Phase 2	NCT05952037	R/R WM	105	Zanubrutinib	MRR	Enrolling
BGB-11417-204	Phase 2	NCT06637501	TN CLL contribution of components	87	Zanubrutinib	CR/CRi	Enrolling
BGB-11417-301 (CELESTIAL-TNCLL)	Phase 3	NCT06073821	TN CLL/SLL	709	Zanubrutinib	PFS	Enrolling ²
BGB-11417-302 (CELESTIAL-RRMCL)	Phase 3	NCT06742996	R/R MCL	300	Zanubrutinib	PFS	Enrolling
BGB-11417-303 (CELESTIAL-RRCLL)	Phase 3	NCT06943872	R/R CLL/SLL	630	Obinutuzumab, Rituximab	PFS	Enrolling

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

²Global Last Subject Enrolled completed with separate Japan cohort enrollment

Refer to Glossary abbreviations



BGB-16673 BTK CDAC

Potential first-in-class BTK degrader

As of: 23 Jul 2025

Trial	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-16673-101 (CaDAnCe 101)	Phase 1/2	NCT05006716	B-Cell Malignancies	621	–	TEAEs	Enrolling
BGB-16673-102	Phase 1	NCT05294731	B-Cell Malignancies	146	–	TEAEs, RP2D, ORR	Enrolling
BGB-16673-104	Phase 1/2	NCT06634589	B-Cell Malignancies	80	Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab	DLTs, TEAEs	Enrolling
BGB-16673-302 (CaDAnCe 302)	Phase 3	NCT06846671	R/R CLL/SLL (investigators choice)	250	–	PFS	Enrolling
BGB-16673-303 (CaDAnCe 303)	Phase 3	NCT06970743	R/R CLL/SLL (CN)	150	–	PFS	Enrolling
BGB-16673-304 (CaDAnCe 304)	Phase 3	NCT06973187	R/R CLL/SLL (vs pirtobrutinib)	500	–	PFS	Start-up

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations



Phase 1 – other hematology assets

As of: 23 Jul 2025

Trial	MOA	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-21447-101	BCL2i	Phase 1	NCT05828589	B-cell malignancies	112	-	DLTs, AEs, TLS	Enrolling

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations



TEVIMBRA®

Poised for global patient impact

As of: 23 Jul 2025

Trial	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-103	Phase 1	NCT06091943	Subcutaneous administration	60	-	Bioavailability and Safety	Closeout
BGB-HNSCC-201	Phase 2	NCT05909904	1L HNSCC	160	LAG3, TIM3	ORR	Closeout
BGB-LC-201	Phase 2	NCT05635708	1L NSCLC	319	LAG3, OX40, HPK1, Chemotherapy	ORR	Closeout
BGB-A317-310 (RATIONALE-310)	Phase 3	NCT03967977	1L UBC	420	Chemotherapy	OS (ITT)	Enrolling
BGB-A317-311 (RATIONALE-311)	Phase 3	NCT03957590	Localized ESCC	366	Chemotherapy + Radiotherapy	PFS	Closeout
BGB-A317-314	Phase 3	NCT04486391	R/R cHL	123 (CN)	Chemotherapy	PFS	Maintenance
BGB-A317-316	Phase 3	NCT07043400	Subcutaneous Formulation ³	351	Chemotherapy	AUC	Start-up
BGB-A317-203	Phase 2	NCT03209973	R/R cHL	68	-	ORR	Approved ²
BGB-A317-204	Phase 2	NCT04004221	2L UC	110	-	ORR	Approved ²
BGB-A317-312 (RATIONALE-312)	Phase 3	NCT04005716	1L ES-SCLC	455	Chemotherapy	OS	Approved
BGB-A317-315 (RATIONALE-315)	Phase 3	NCT04379635	Neo/adj NSCLC	450	Chemotherapy	MPR, EFS	Approved



¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

²Approved only in China

³Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Refer to Glossary abbreviations



TEVIMBRA®

Poised for global patient impact

As of: 23 Jul 2025

Trial	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-208	Phase 2	NCT03419897	2L+ HCC	250	-	ORR	Approved ²
BGB-A317-209	Phase 2	NCT03736889	Late Line MSI-H or dMMR Solid Tumors	150	-	ORR	Approved ²
BGB-A317-301 (RATIONALE-301)	Phase 3	NCT03412773	1L HCC	680	-	OS	Approved
BGB-A317-302 (RATIONALE-302)	Phase 3	NCT03430843	2L ESCC	489	-	OS	Approved
BGB-A317-303 (RATIONALE-303)	Phase 3	NCT03358875	2/3L NSCLC	805	-	OS (PDL1+), OS	Approved
BGB-A317-304 (RATIONALE-304)	Phase 3	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	PFS	Approved
BGB-A317-305 (RATIONALE-305)	Phase 3	NCT03777657	1L GC	978	Chemotherapy	OS	Approved
BGB-A317-306 (RATIONALE-306)	Phase 3	NCT03783442	1L ESCC	650	Chemotherapy	OS	Approved
BGB-A317-307 (RATIONALE-307)	Phase 3	NCT03594747	1L Sq. NSCLC	342	Chemotherapy	PFS	Approved
BGB-A317-309 (RATIONALE-309)	Phase 3	NCT03924986	1L NPC	263	Chemotherapy	PFS	Approved



¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

²Approved only in China

Refer to Glossary abbreviations



Phase 1 – other solid tumor assets

As of: 23 Jul 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-43395-101	BGB-43395	CDK4i	Ph1	NCT06120283	Solid Tumors	300	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
BGB-43395-102	BGB-43395	CDK4i	Ph1	NCT06253195	Solid Tumors	33	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-68501-101	BG-68501	CDK2i	Ph1	NCT06257264	Solid Tumors	218	BGB-43395, Fulvestrant	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C9074-101	BGB-C9074	B7-H4 ADC	Ph1	NCT06233942	Solid Tumors	227	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose Escalation
BGB-21447-102	BGB-21447	BCL2i	Ph1	NCT06756932	2L+ HR+/HER2- BC	92	Fulvestrant ± BGB-43395	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-B455-101	BGB-B455	Claudin 6 x CD3 BsAb	Ph1	NCT06803680	Solid Tumors	80	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-60366-101	BG-60366	EGFR CDAC	Ph1	NCT06685718	Solid Tumors	93	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BGB-58067-101	BGB-58067	PRMT5i	Ph1	NCT06589596	Solid Tumors	92	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
SHY2039-001	BG-89894	MAT2Ai	Ph1	NCT06568614	Solid Tumors	140	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-T187-101	BG-T187	EGFR x MET x MET TsAb	Ph1	NCT06598800	Solid Tumors	87	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BGB-C354-101	BGB-C354	B7-H3 ADC	Ph1	NCT06422520	Solid Tumors	62	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-53038-101	BGB-53038	Pan-KRASi	Ph1	NCT06585488	Solid Tumors	177	Tislelizumab, Cetuximab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations



Phase 1 – other solid tumor assets

As of: 23 Jul 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BG-C137-101	BG-C137	FGFR2b ADC	PhI	NCT06625593	Solid Tumors	68	-	AE, SAE, DLT, MTD, RDfE, ORR	Dose Escalation
BG-C477-101	BG-C477	CEA ADC	PhI	NCT06596473	Solid Tumors	21	Chemotherapy	AE, SAE, DLT, MTD, RDfE, ORR	Dose Escalation
BGB-B2033-101	BGB-B2033	GPC3 x 4-1BB BsAb	PhI	NCT06427941	Solid Tumors	140	Tislelizumab	AE, SAE, DLT, MTD, RP2D	Dose Escalation
BGB-B3227-101	BGB-B3227	MUC1 x CD16A BsAb	PhI	NCT06540066	Solid Tumors	75	Tislelizumab, Chemotherapy	AE, SAE, DLT, MTD, RDfE	Dose Escalation
BGB-R046-101	BGB-R046	IL-15 prodrug	PhI	NCT06487858	Solid Tumors	74 (CN)	Tislelizumab	AE, SAE, DLT, MTD, RDfE, ORR	Dose Escalation
BGB-A317-26808-101	BGB-26808	HPKli	PhI	NCT05981703	Solid Tumors	107	Tislelizumab	AE, SAE, DLT, MTD, RDfE, ORR	Dose Expansion
BGB-A317-30813-101	BGB-30813	DGKζi	PhI	NCT05904496	Solid Tumors	41	Tislelizumab	TEAE, SAE, DLT, MTD, RDfE, ORR	Closeout
BGB-A317-A3055-101	BGB-A3055	CCR8 mAb	PhI	NCT05935098	Solid Tumors	94	Tislelizumab	TEAE, SAE, DLT, MTD, RDfE, ORR	Dose Escalation
AMG757 20230298 (DeLLphi-308)	Tarlatamab	DLL3 x CD3 BiTE® (Subq)	PhI	NCT06598306	2L+ SCLC ²	100 ³	-	DLTs, SAEs, TEAEs	Start-up
AMG757 20240124 (DeLLphi-310)	Tarlatamab	DLL3 x CD3 BiTE® (+B7-H3)	PhI	NCT06898957	2L+ SCLC	200 ³	YL201	DLTs, TEAEs	Enrolling
AMG509 20180146	Xaluritamig	STEAP1 x CD3 XmaB®	PhI	NCT04221542	mCRPC	470 ³	-	TEAEs, DLTs	Enrolling
BGB-290-102	Pamiparib	PARPi	PhI	NCT03333915	3L+ PSOC, PROC	113	-	TEAE, SAE, ORR	Approved
BGB-A317-15025-101	BGB-15025	HPKli	PhI	NCT04649385	Solid Tumors	157	Tislelizumab	AE, SAE, DLT, MTD, RDfE, ORR	Closeout
BGB-24714-101	BGB-24714	SMAC Mimetic	PhI	NCT05381909	Solid Tumors	160	Chemotherapy	AE, TEAE, SAE, DLT, MTD, RDfE, ORR	Closeout

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

²Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

³Total planned enrollment, with BeOne territories included

Refer to Glossary abbreviations



Phase 2 – other solid tumor assets

As of: 23 Jul 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
ZWI-ZW25-203 (HERIZON-BTC-01)	Zanidatamab	HER2 BsAb	Ph2	NCT04466891	2L+ BTC	55	–	ORR	Approved ²
AMG757 20230273 (DeLLphi-307)	Tarlatamab	DLL3 x CD3 BiTE®	Ph2	NCT06502977	3L+ SCLC	32 (CN)	–	ORR	Maintenance
AMG757 20240092 (DeLLphi-309) (Alt dosing)	Tarlatamab	DLL3 x CD3 BiTE®	Ph2	NCT06745323	2L SCLC	240 ³	–	ORR	Enrolling
BGB-A317-A445-201	BGB-A445	OX40 mAb	Ph2	NCT05661955	Melanoma, UC	113	Tislelizumab	ORR	Closeout
BGB-LBL-007-201	BGB-LBL-007	LAG3 mAb	Ph2	NCT05609370	MSS-CRC	113	Tislelizumab, Chemotherapy, Bevacizumab	PFS, AE, SAE	Closeout
BGB-LBL-007-202	BGB-LBL-007	LAG3 mAb	Ph2	NCT06010303	1L ESCC	118	Tislelizumab, Chemotherapy	ORR	Closeout

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

²Approved only in China

³Total planned enrollment, with BeOne territories included

Refer to Glossary abbreviations



Phase 3 – other solid tumor assets

As of: 23 Jul 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20240178 (DeLLphi-312) (Induction + Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT07005128	1L ES-SCLC ²	330 ³	durvalumab +chemo (induction); durvalumab (maintenance)	OS	Start up
AMG757 20200041 (DeLLphi-305) (Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT06211036	1L ES-SCLC	550 ³	durvalumab (maintenance)	OS	Enrolling
AMG757 20230016 (DeLLphi-306)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT06117774	LS-SCLC	400 ³	-	PFS	Enrolling
AMG757 20210004 (DeLLphi-304)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT05740566	2L SCLC	509 ³	-	OS	Maintenance
BGB-A317-290-LTE1	Internal assets	Multiple	Ph3	NCT04164199	Multiple	430 ⁴	Multiple	Immune mediated adverse events	Enrolling
ZWI-ZW25-301 (HERIZON-GEA-01)	Zanidatamab	HER2 BsAb	Ph3	NCT05152147	1L HER2+ GEA	439	tislelizumab ± chemo	PFS, OS	Maintenance
BGB-290-302	Pamiparib	PARPi	Ph3	NCT03519230	2L PSOC	224	-	PFS	Maintenance
BGB-A317-A1217-302 (AdvanTIG-302)	Ociperlimab	TIGIT mAb	Ph3	NCT04746924	1L NSCLC (PDL1 H)	669	Tislelizumab	OS	Closeout

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

²Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

³Total planned enrollment, with BeOne territories included

⁴Currently enrolled patients, more patients may be enrolled in future

Refer to Glossary abbreviations



Immunology and inflammation assets

As of: 23 Jul 2025

Trial	MOA	Phase	CT.gov	Population	Total Patients ¹	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-16673-107	BTK CDAC	PhI	NCT07005713	Chronic spontaneous urticaria (CSU)	27	-	Incidence and severity of TEAE	Enrolling
BGB-3111-309	BTKi	Ph2/3	NCT05707377	Primary Membranous Nephropathy	282	-	Urine Protein Creatinine Ratio, Complete Remission	Enrolling
BGB-45035-101	IRAK4 CDAC	PhI	NCT06342713	Healthy volunteers and patients with atopic dermatitis or prurigo nodularis	195	-	Incidence and severity of TEAE	Enrolling

¹Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations



Full list of commercial and clinical assets

Commercial			Pipeline					
Product	Commercial Rights	Partner	Asset	Latest Stage	Partner	Asset	Latest Stage	Partner
BRUKINSA® (zanubrutinib)	Global	-	Sonrotoclax (BCL2i)	Ph3	-	BG-60366 (EGFR CDAC)	Ph1	-
TEVIMBRA® (tislelizumab)	Global	-	BGB-16673 (BTK CDAC)	Ph3	-	BG-T187 (EGFR x MET x MET TsAb)	Ph1	-
PARTRUVIX® (pamiparib)	Global	-	BGB-21447 (BCL2i)	Ph1	-	BGB-R046 (IL-15 prodrug)	Ph1	-
IMDELLTRA® (tarlatamab) ¹	China	Amgen	BGB-43395 (CDK4i)	Ph1	-	BGB-26808 (HPK1i)	Ph1	-
XGEVA® (denosumab)	China	Amgen	BG-C9074 (B7-H4 ADC)	Ph1	Duality Bio	BGB-53038 (Pan-KRAsi)	Ph1	-
BLINCYTO® (blinatumomab)	China	Amgen	BGB-68501 (CDK2i)	Ph1	Ensem	BG-C477 (CEA ADC)	Ph1	-
KYPROLIS® (carfilzomib)	China	Amgen	BGB-A3055 (CCR8 mAb)	Ph1	-	BG-C137 (FGFR2b ADC)	Ph1	-
ZIIHERA® (zanidatamab)	China	Zymeworks / Jazz	BGB-B445 (Claudin 6 x CD3 BsAb)	Ph1	-	BGB-3227 (MUC1 x CD16A BsAb)	Ph1	-
SYLVANT® (siltuximab)	China	Recordati	BG-58067 (MTA Coop PRMT5i)	Ph1	-	BGB-B2033 (GPC3x4-1BB BsAb)	Ph1	-
QARZIBA® (dinutuximab)	China	Recordati	BG-89894 (MAT2Ai)	Ph1	CSPC	Xaluritamig (STEAP1 x CD3 XmAb®) ²	Ph1	Amgen
TAFINLAR® (dabrafenib)	China	Novartis	BGB-C354 (B7-H3 ADC)	Ph1	-	BGB-45035 (IRAK4 CDAC)	Ph1	-
MEKINIST® (trametinib)	China	Novartis						
VOTRIENT® (pazopanib)	China	Novartis						
AFINITOR® (everolimus)	China	Novartis						
ZYKADIA® (ceritinib)	China	Novartis						
POBEVCY® (Avastin biosimilar)	China	Bio-Thera						
BAITUOWEI® (goserelin microspheres for injection)	China	Luye Pharma						

¹Amgen collaboration. BeOne has tiered mid-single digit royalties on net sales

²Study is being conducted in China as part of the BeOne-Amgen collaboration



Glossary

Disease abbreviations

AD	Atopic dermatitis	mCRPC	Metastatic castration resistant prostate cancer
AML	Acute myeloid leukemia	MDS	Myelodysplastic syndromes
BP-ALL	B-precursor acute lymphocytic leukemia	MM	Multiple myeloma
BTC	Biliary tract cancer	MSI-H	Microsatellite stability high
CHL	Classic Hodgkin's lymphoma	MSS CRC	Microsatellite stable colorectal cancer
CLL	Chronic lymphocytic leukemia	MTx	Maintenance
CSU	Chronic spontaneous urticaria	MZL	Marginal zone lymphoma
dMMR	Deficient DNA mismatch repair	Neo/adj	Neoadjuvant/adjuvant
DLBCL	Diffuse large B-cell lymphoma	NSCLC	Non-small cell lung cancer
ES-SCLC	Extensive stage small cell lung cancer	NPC	Nasopharyngeal carcinoma
ESCC	Esophageal squamous cell carcinoma	PMN	Primary membranous nephropathy
FL	Follicular lymphoma	PN	Prurigo nodularis
GEA	Gastroesophageal adenocarcinoma	PSR OC	Platinum sensitive recurrent ovarian cancer
GC	Gastric cancer	R/R	Relapsed or refractory
HCC	Hepatocellular carcinoma	SCLC	Small cell lung cancer
HNSCC	Head and neck squamous cell carcinoma	SLL	Small lymphocytic lymphoma
LS-SCLC	Limited stage small cell lung cancer	UC / UBC	Urinary / bladder cancer
MCL	Mantle cell lymphoma	WM	Waldenström's macroglobulinemia

Other abbreviations

ADC	Antibody drug conjugate	MTD	Maximum tolerated dose
AE	Adverse event	MTx	Maintenance
BiTE®	Bi-specific T-cell engager	NME	New Molecular Entity
CDAC	Chimeric degradation activation compound	ORR	Objective response rate
CR	Complete response	OS	Overall survival
DCR	Disease control rate	PCR	Pathologic complete response
DLT	Dose-limiting toxicity	PFS	Progression-free survival
DOR	Duration of response	RDfE	Recommended dose for expansion
EFS	Event free survival	RP2D	Recommended phase 2 dose
HV	Healthy volunteers	SAE	Severe adverse event
LCM	Lifecycle management	TEAE	Treatment emergent adverse event
LTE	Long-term extension	TN	Treatment naïve
mAb	Monoclonal antibody	TsAb	Tri-specific antibody
mOR	Modified overall response	VGPR	Very good partial response
MPR	Major pathological response	XmAb®	XmAb is a registered trademark of Xencor, Inc.

